[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356493-105":59,"doc-detail-356493-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ulk1-promotes-metastatic-progression-in-experimental-models-of-epithelial-ovarian-cancer","ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer","","Epithelial ovarian cancer (EOC) drives high gynecological cancer mortality due to late diagnosis and chemoresistance. The study examines ULK1, a key autophagy regulator, in EOC progression where autophagy supports spheroid survival during metastasis. Using CRISPR/Cas9 to delete ULK1 in multiple EOC cell lines and a fallopian tube epithelial line, the work confirms autophagy disruption, reduced spheroid viability, impaired organoid growth, and diminished metastasis in xenografts. Proteomics identify disrupted MEK-MAPK and PI3K-AKT-mTOR pathways, with enhanced sensitivity to MEK and mTOR inhibition, while DCC-3116 shows heterogeneous effects in patient-derived organoids.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ulk1-promotes-metastatic-progression-in-experimental-models-of-epithelial-ovarian-cancer/356493/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ulk1-promotes-metastatic-progression-in-experimental-models-of-epithelial-ovarian-cancer/356493.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary goal of the study on ULK1 in epithelial ovarian cancer?","Question",{"text":113,"@type":114},"To determine whether ULK1 regulates autophagy-related processes that support EOC spheroid survival, tumor growth, and metastatic progression, and to clarify the underlying mechanisms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did the researchers disrupt ULK1 activity in EOC models?",{"text":118,"@type":114},"They used CRISPR/Cas9 to delete ULK1 in EOC cell lines (including OVCAR8, HEYA8, and ES2) and a fallopian tube epithelial cell line, then validated ULK1 loss and autophagy disruption in spheroids.",{"name":120,"@type":111,"acceptedAnswer":121},"What key outcomes did ULK1 loss produce in tumor and metastasis experiments?",{"text":122,"@type":114},"ULK1 knockout reduced spheroid viability via increased apoptosis, impaired matrix-bound organoid growth, decreased metastatic potential in in vivo xenografts, and reduced invasive capacity in mesothelial clearance assays.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356493,1790528250,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer  \nJack D. Webb 1,2, Adrian Buensuceso1, Emily J. Tomas 1,2, Matthew J. Borrelli1,2, Lauren Viola1, Owen Hovey3, Yudith Ramos Valdes1, Bipradeb Singha 1, Shawn S-C Li 3 and Trevor G. Shepherd 1,2,4,5 ✉  \n© The Author(s) 2026  \n\n|  | Epithelial ovarian cancer (EOC) is a leading cause of gynecological cancer mortality, driven largely by late diagnosis and chemoresistance. While autophagy is critical for EOC spheroid survival during metastasis, the role of ULK1, a key regulator of autophagy, in EOC progression remains unclear. To investigate this, we utilized CRISPR/Cas9 technology to delete ULK1 in EOC cell lines OVCAR8, HEYA8, ES2 and the fallopian tube epithelial cell line FT190 . ULK1 loss and autophagy disruption were conﬁrmed in EOC spheroids, with reduced Beclin-1 phosphorylation, impaired LC3 processing, and p62 accumulation. ULK1 knockout decreased EOC spheroid cell viability via increased apoptosis, and impaired matrix-bound organoid growth, offering new insights into ULK1 activity in affecting EOC tumor growth and spread. These ﬁndings were supported by in vivo xenograft models, in which ULK1 loss signiﬁcantly reduced tumor burden and metastatic potential. ULK1 requirement during metastasis was supported by diminished invasive capacity of ULK1 knockout spheroid cells in mesothelial clearance assays. To investigate ULK1 mechanisms contributing to EOC tumor progression and metastasis, we conducted proteomic analyses of OVCAR8 spheroids, which revealed ULK1 loss disrupted critical pathways, including MEK-MAPK, PI3K-AKT-mTOR, and apoptosis regulation. Although ULK1 knockout failed to synergize with standard-of-care chemotherapeutics, it signiﬁcantly enhanced sensitivity to MEK and mTOR inhibition. Analysis of ovarian cancer datasets demonstrates that high ULK1 mRNA correlates with a poorer 10-year overall and progression-free survival; in fact, its expression is further elevated in metastases as compared with primary tumors and normal tissue. Treatment of metastatic patient-derived organoids with the clinical ULK1 inhibitor DCC-3116, MEK inhibitor trametinib, or mTORC1/2 inhibitor AZD-8055 reduced viability in a subset of these samples, reﬂecting inter-patient heterogeneity and need for biomarker-guided selection. Overall, this study highlights ULK1 as a critical regulator of multiple steps of EOC disease progression, underscoring its potential as a |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| therapeutic target in advanced ovarian cancer. |  |  |\n|  | Oncogene (2026) 45:1111–1127; [https://doi.org/10.1038/s41388-026-03702-2](https://doi.org/10.1038/s41388-026-03702-2) |  |\n|  |  |  |\n\nBACKGROUND  \nEpithelial ovarian cancer (EOC) has the ﬁfth-highest death-toincidence ratio for all cancers in women and is the leading cause of death from gynecologic cancers due to its late-stage diagnosis and lack of effective strategies for treating chemoresistant disease [1] . Patients with EOC are typically treated with aggressive surgical debulking and cytotoxic carboplatin/paclitaxel combination chemotherapy; however, nearly 80% of these patients relapse within ﬁve years [2] . Investigations into the mechanisms that support cell survival during metastasis andregrowth of refractory EOC cells after treatment are of critical importance and are an area of active research. EOC spreads by tumor cells disseminating directly into the peritoneal space, often suspended in ascites, and then attach to the serosal surfaces of the abdominal cavity to form secondary deposits [3, 4] . Clusters of metastatic EOC cells known as spheroids accumulate in the malignant ﬂuid of patients with advanced disease [5] . Spheroids are known to promote metas","cbCainxMQfitSjh2","https://ap.wps.com/l/cbCainxMQfitSjh2","pdf",7086491,17,"English","# Article Open\n## Background\n## Methods and Key Findings (Study Summary)","[{\"question\":\"What was the primary goal of the study on ULK1 in epithelial ovarian cancer?\",\"answer\":\"To determine whether ULK1 regulates autophagy-related processes that support EOC spheroid survival, tumor growth, and metastatic progression, and to clarify the underlying mechanisms.\"},{\"question\":\"How did the researchers disrupt ULK1 activity in EOC models?\",\"answer\":\"They used CRISPR/Cas9 to delete ULK1 in EOC cell lines (including OVCAR8, HEYA8, and ES2) and a fallopian tube epithelial cell line, then validated ULK1 loss and autophagy disruption in spheroids.\"},{\"question\":\"What key outcomes did ULK1 loss produce in tumor and metastasis experiments?\",\"answer\":\"ULK1 knockout reduced spheroid viability via increased apoptosis, impaired matrix-bound organoid growth, decreased metastatic potential in in vivo xenografts, and reduced invasive capacity in mesothelial clearance assays.\"}]","ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer | PDF",1790125556,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2713e5390ed33c9363f9366da0112681.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80641bf164fa63df8018c47371c3c441.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/030bbe45913b0947021de397f4ae2db4.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c57e687224fbb63089b7f481746728f.webp",980,1301]